【摘要】：目的:探討冠心病患者應(yīng)用多索茶堿治療替格瑞洛相關(guān)呼吸困難的安全性及有效性。方法:選取2015-02至2016-07期間在鄭州大學(xué)第一附屬醫(yī)院心內(nèi)科服用替格瑞洛后出現(xiàn)相關(guān)呼吸困難的冠心病患者172例,隨機(jī)分為干預(yù)組(n=86)及對(duì)照組(n=86)。干預(yù)組給予多索茶堿片(商品名:安賽瑪,規(guī)格:200 mg/片)早晚各1片,服用5天;對(duì)照組給予安慰劑。記錄兩組1天后呼吸困難總緩解率,治療前、后血小板聚集率以及6個(gè)月心原性死亡、心肌梗死、卒中、出血等心血管不良事件的發(fā)生率。結(jié)果:應(yīng)用多索茶堿1天后,干預(yù)組呼吸困難緩解率明顯高于對(duì)照組(93%vs 63%,P0.05);服用多索茶堿前、后,兩組血小板聚集率差異均無統(tǒng)計(jì)學(xué)意義(P0.05);兩組心血管不良事件的發(fā)生率無差異(P0.05)。結(jié)論:多索茶堿治療替格瑞洛相關(guān)呼吸困難有效,并且不影響替格瑞洛抗血小板聚集作用。
[Abstract]:Objective: to investigate the safety and efficacy of doxophylline in the treatment of tigrilo-associated dyspnea in patients with coronary heart disease. Methods: 172 patients with coronary heart disease associated with dyspnea were randomly divided into intervention group (n = 86) and control group (n = 86) during 2015-02 to 2016-07 in Department of Cardiology, first affiliated Hospital of Zhengzhou University. The intervention group received doxofylline tablets (trade name: Ansama, specification: 200 mg/ tablets) 1 tablet in the morning and evening for 5 days, while the control group was given placebo. The total remission rate of dyspnea, the platelet aggregation rate before and after treatment and the incidence of cardiovascular adverse events such as cardiac death, myocardial infarction, stroke and hemorrhage were recorded in both groups. Results: the remission rate of dyspnea in the intervention group was significantly higher than that in the control group (P 0.05), but there was no significant difference in platelet aggregation rate between the two groups before and after the administration of doxofylline (P0.05). There was no difference in the incidence of cardiovascular adverse events between the two groups (P0.05). Conclusion: doxofylline is effective in the treatment of tigrilo-associated dyspnea and does not affect the antiplatelet aggregation of tigrilol.
【作者單位】： 鄭州大學(xué)第一附屬醫(yī)院心內(nèi)科;
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 楊娜;王小妮;;多索茶堿治療慢性肺源性心臟病致不良反應(yīng)臨床觀察[J];臨床合理用藥雜志;2010年13期

，

本文編號(hào)：2302670